Forest antidepressant Viibryd succeeds in anxiety disorder trials
June 23, 2014 at 16:54 PM EDT
June 23 (Reuters) - Forest Laboratories Inc, which is being acquired by generic drugmaker Actavis Plc, said on Monday that its antidepressant Viibryd performed significantly better than a placebo for treating generalized anxiety disorder, according to data from three late-stage studies.